HEALTH

Private label, Bayer drive down internal analgesics

BY DSN STAFF

Internal analgesics is slightly down in retail sales with a 0.6% decrease year-over-year. As the largest segment in internal analgesics, tablets were down 0.4%. This performance was driven down primarily by private label and Bayer products. Private-label internal analgesics were down 5%, and Bayer was down 4%. Pfizer saw no change in sales. McNeil’s return to the market did well, reflecting a 17% increase over the same time period last year. The external analgesic category was up 7% year-over-year. The increase was driven by Chattem (up 20%) and Hisamitsu (up 8%), while private label was down year-over-year by 2% (see Figure 1).

(To view the full Promo Watch report, click here.)

On average, external analgesic products reflected higher retail margins than internal analgesics. Both Chattem and Hisamitsu products saw similar retail margins at 47% and 49%, respectively, in the drug channel, with 29% and 30%, respectively, in the mass channel. Pfizer products exhibited the lowest average retail margins at just 14% in mass, followed by Bayer at 16% (see Figure 2).

For feature ads, Advil and Tylenol were featured far more than the other leading brands. Advil increased in features for this year from 3,571 to 3,789 in the food, drug and mass channels, and Tylenol similarly increased from 3,605 to 3,761. Aleve and Excedrin also increased year-over-year, while Bayer was the only leading brand to see a decrease in ads, from 1,133 to 1,012 in food, drug and mass (see Figure 3).

Drug Store News has partnered with Competitive Promotion Report, IRI and MarketTrack to create this exclusive report. This article highlights the market performance of major manufacturers in pain treatments — internal and external analgesic categories. The result in this study reflects the leading brands/manufacturers in each segment in terms of retail sales, average retailer margins and promotional ad activity.

CPR is a leading provider of competitive market intelligence and insights in the health, beauty and wellness industry. Learn more by visiting competitivepromotion.com.

Want more Promo Watch? Visit DrugStoreNews.com/promo-watch-1.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

CHPA Educational Foundation Gala 2016 coming to NYC’s Rainbow Room

BY David Salazar
NEW YORK — CHPA and the CHPA Educational Foundation will be holding the CHPA Educational Foundation Gala 2016 in New York City on November 14. The boards of both organizations will be in attendance at the gala, which will be held at the Rainbow Room, located atop 30 Rockefeller Plaza. 
 
The gala will include a reception from 6-7 p.m., followed by dinner and an awards presentation from 7-9 p.m. and a dessert reception from 9-10 p.m. The program will include recognition and remarks from healthcare community members who have worked with the CHPA Educational Foundation to advance public education about OTC medicines and dietary supplements. 
 
Three companies will be honored at the gala, including Walmart, which is receiving the 2016 Distinguished Industry Partner of the Year award and the American Association of Poison Control Centers, which is receiving the 2016 Outstanding Community Partner of the Year award. A third, CHPA member company will be honored with the 2016 Industry Leadership Award for Advancing Responsible Self-Care. 
 
For information about sponsorship and attendance, visit the CHPA Education Foundation Gala 2016 website.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Hisamitsu launches Salonpas gel patch

BY David Salazar
FLORHAM PARK, N.J. — Hisamitsu America has launched the new Salonpas Lidocaine 4% Pain Relieving Gel-Patch, the company announced Monday. The patch includes the maximum strength lidocaine available without a prescription and uses a proprietary hydro-gel technology to soothe aggravated nerves, the company said.
 
“We developed the Salonpas Lidocaine 4% Pain Relieving Gel-Patch to be as close as possible to the 5% prescription Lidocaine patches. Our Lidocaine is delivered using our proprietary coating technology which ensures precise and even delivery of medicine at the site of pain,” Hisamitsu America president and CEO John Incledon said. “These unscented patches provide numbing relief to desensitize aggravated nerves for hours of pain relief.”
 
The patch retails for $11.99 and is available at leading retailers nationwide, Hisamitsu said. 
 
“I tried the Salonpas Lidocaine 4% Pain Relieving Gel-Patch after a rigorous paddle-boarding session to address my 'tennis elbow' and found that the patch worked as effectively as a much stronger prescription patch," journalist Dr. Bob Arnot said. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?